From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

DARPA Biologically-Derived Medicines on Demand BAA

by Global Biodefense Staff
March 26, 2012

The Defense Advanced Research Projects Agency (DARPA) is seeking proposals on development of novel devices and techniques to produce multiple protein biologics in response to specific battlefield threats and medical needs under a new BAA for Biologically-Derived Medicines on Demand (Bio-MOD).

One focus area of the program is on novel and flexible methodologies for genetic engineering or modification of polypeptide synthesis systems (such as prokaryotes, eukaryotes, and cell-free translation systems) to produce multiple therapeutics in response to specific demands. Example approaches include nutrient activation where nutrient type or concentration triggers specific therapeutic output; photoactivation where light intensity or wavelength inputs triggers therapeutic output; and pH activation where pH of solution triggers therapeutic output.

The second component of the BAA is for flexible, portable device platforms for manufacturing multiple biologics with high purity, efficacy and potency at the point-of-care, in short timeframes, when the specific need arises.  Therapeutics to be pursued in the program is not detailed by DARPA; however, they do generalize that they must be protein-based biologics previously approved by the FDA and widely relevant to the Department of Defense and national security.

Further details are available under Solicitation Number: DARPA-BAA-12-37.  Proposal abstracts are due April 24, 2012 and the full response deadline is Jun 12, 2012.

From Our Partners
Tags: BAADARPAPOC Diagnostics

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC